Evaluation of the long-term efficacy and safety of indoprofen in rheumatoid arthritis and osteoarthritis patients.
Thirty-seven adult out-patients of both sexes, suffering from classical or definite rheumatoid arthritis (R.A.) or osteoarthritis (O.A.), were given indoprofen 600 mg/day for up to 5 months, in order to evaluate its effectiveness and safety. A significant improvement of joint tenderness (Ritchie) and of functional index (Lee) was rapidly achieved in R.A. patients (12 cases); objective signs of inflammation, moreover, were gradually relieved. In O.A. patients (25 cases) articular pain, motility and swelling all improved in about 90% of cases. A complete set of laboratory tests reflecting blood picture, liver and kidney function, carried out at monthly intervals during the study, failed to reveal any sign of toxicity. Clinical tolerance was generally good.
D000368:Aged; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006403:Hematologic Tests; D006801:Humans; D007216:Indoprofen / Q000627:therapeutic use*; D007677:Kidney Function Tests; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000175:diagnosis / Q000188:drug therapy*; D010666:Phenylpropionates / Q000627:therapeutic use*
D010666:Phenylpropionates; D007216:Indoprofen